80 related articles for article (PubMed ID: 27939411)
1. Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis.
Maru Y; Tanaka N; Ohira M; Itami M; Hippo Y; Nagase H
Gynecol Oncol; 2017 Feb; 144(2):377-383. PubMed ID: 27939411
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide DNA methylation in relation to ARID1A deficiency in ovarian clear cell carcinoma.
Li S; Meersma GJ; Kupryjanczyk J; de Jong S; Wisman GBA
J Transl Med; 2024 Jun; 22(1):556. PubMed ID: 38858765
[TBL] [Abstract][Full Text] [Related]
3. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.
Jones S; Wang TL; Shih IeM; Mao TL; Nakayama K; Roden R; Glas R; Slamon D; Diaz LA; Vogelstein B; Kinzler KW; Velculescu VE; Papadopoulos N
Science; 2010 Oct; 330(6001):228-31. PubMed ID: 20826764
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of molecular profiles and molecular signatures in clear cell ovarian cancer.
Schnack TH; Oliveira DNP; Christiansen AP; Høgdall C; Høgdall E
Cancer Genet; 2023 Nov; 278-279():9-16. PubMed ID: 37567101
[TBL] [Abstract][Full Text] [Related]
5. Detection of Biallelic Loss of DNA Repair Genes in Formalin-Fixed, Paraffin-Embedded Tumor Samples Using a Novel Tumor-Only Sequencing Panel.
Glodzik D; Selenica P; Rogge RA; Silverman IM; Mandelker D; Harris S; Zhao J; Zinda M; Veloso A; Malani N; Riaz N; Koehler M; Daber RD; Johnson V; Rimkunas V; Reis-Filho JS
J Mol Diagn; 2023 May; 25(5):295-310. PubMed ID: 36944408
[TBL] [Abstract][Full Text] [Related]
6. The Potential Role of Complement System in the Progression of Ovarian Clear Cell Carcinoma Inferred from the Gene Ontology-Based Immunofunctionome Analysis.
Su KM; Lin TW; Liu LC; Yang YP; Wang ML; Tsai PH; Wang PH; Yu MH; Chang CM; Chang CC
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316695
[TBL] [Abstract][Full Text] [Related]
7. Impact of DNA integrity on the success rate of tissue-based next-generation sequencing: Lessons from nationwide cancer genome screening project SCRUM-Japan GI-SCREEN.
Kuwata T; Wakabayashi M; Hatanaka Y; Morii E; Oda Y; Taguchi K; Noguchi M; Ishikawa Y; Nakajima T; Sekine S; Nomura S; Okamoto W; Fujii S; Yoshino T;
Pathol Int; 2020 Dec; 70(12):932-942. PubMed ID: 33030786
[TBL] [Abstract][Full Text] [Related]
8. APOBEC3B stratifies ovarian clear cell carcinoma with distinct immunophenotype and prognosis.
Long X; Lu H; Cai MC; Zang J; Zhang Z; Wu J; Liu X; Cheng L; Cheng J; Cheung LWT; Shen Z; Zhou Y; Di W; Zhuang G; Yin X
Br J Cancer; 2023 Jun; 128(11):2054-2062. PubMed ID: 36997661
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Somatic Mutation Profiles Between Formalin-Fixed Paraffin Embedded Tissues and Plasma Cell-Free DNA from Ovarian Cancer Patients Before and After Surgery.
Jagelkova M; Zelinova K; Laucekova Z; Bobrovska M; Dankova Z; Grendar M; Dokus K
Biores Open Access; 2020; 9(1):73-79. PubMed ID: 32219013
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Molecular Profiling and Clinicopathological Characteristics of Gastric-Type Mucinous Carcinoma of the Uterine Cervix in Japanese Women.
Nasu H; Nishio S; Park J; Tasaki K; Terada A; Tsuda N; Kawano K; Kojiro-Sanada S; Akiba J; Ushijima K
Kurume Med J; 2024 May; 69(3.4):237-249. PubMed ID: 38369337
[TBL] [Abstract][Full Text] [Related]
11. Primary urethral clear-cell adenocarcinoma: comprehensive analysis by surgical pathology, cytopathology, and next-generation sequencing.
Mehra R; Vats P; Kalyana-Sundaram S; Udager AM; Roh M; Alva A; Pan J; Lonigro RJ; Siddiqui J; Weizer A; Lee C; Cao X; Wu YM; Robinson DR; Dhanasekaran SM; Chinnaiyan AM
Am J Pathol; 2014 Mar; 184(3):584-91. PubMed ID: 24389164
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive characterization of genomic features and clinical outcomes following targeted therapy and secondary cytoreductive surgery in OCCC: a single center experience.
Wijaya ST; Ngoi NY; Loh JW; Tan TZ; Lim D; Khan IS; Thian YL; Lai A; Ang BW; Tong P; Ng J; Low JJ; Ilancheran A; Lim SE; Lim YW; Tan DS
J Gynecol Oncol; 2024 Mar; ():. PubMed ID: 38606821
[TBL] [Abstract][Full Text] [Related]
13. Genomic Sub-Classification of Ovarian Clear Cell Carcinoma Revealed by Distinct Mutational Signatures.
Oliveira DVNP; Schnack TH; Poulsen TS; Christiansen AP; Høgdall CK; Høgdall EV
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680390
[TBL] [Abstract][Full Text] [Related]
14. Prioritizing Clinically Significant Lung Cancer Somatic Mutations for Targeted Therapy Through Efficient NGS Data Filtering System.
Wang J; Li H; Liu H
AMIA Jt Summits Transl Sci Proc; 2024; 2024():305-313. PubMed ID: 38827108
[TBL] [Abstract][Full Text] [Related]
15. Establishment and characterization of multiple patient-derived organoids from a case of advanced endometrial cancer.
Maru Y; Kohno M; Suzuka K; Odaka A; Masuda M; Araki A; Itami M; Tanaka N; Hippo Y
Hum Cell; 2024 May; 37(3):840-853. PubMed ID: 38546950
[TBL] [Abstract][Full Text] [Related]
16. From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer.
Liu Z; Jing C; Kong F
J Ovarian Res; 2024 Feb; 17(1):39. PubMed ID: 38347608
[TBL] [Abstract][Full Text] [Related]
17. HER2 status as a potential predictive biomarker for ovarian clear cell carcinoma.
Kendall Bártů M; Němejcová K; Michálková R; Stružinská I; Hájková N; Hojný J; Krkavcová E; Laco J; Matěj R; Drozenová J; Méhes G; Fabian P; Hausnerová J; Švajdler M; Škapa P; Cibula D; Zima T; Dundr P
Virchows Arch; 2023 Oct; 483(4):497-507. PubMed ID: 37676270
[TBL] [Abstract][Full Text] [Related]
18. Endometriosis-Associated Ovarian Carcinomas: How PI3K/AKT/mTOR Pathway Affects Their Pathogenesis.
Driva TS; Schatz C; Haybaeck J
Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627318
[TBL] [Abstract][Full Text] [Related]
19. Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery.
Colombo I; Karakasis K; Suku S; Oza AM
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370830
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive molecular analysis of 113 primary ovarian clear cell carcinomas reveals common therapeutically significant aberrations.
Stružinská I; Hájková N; Hojný J; Krkavcová E; Michálková R; Dvořák J; Němejcová K; Matěj R; Laco J; Drozenová J; Fabian P; Hausnerová J; Méhes G; Škapa P; Švajdler M; Cibula D; Frühauf F; Bártů MK; Dundr P
Diagn Pathol; 2023 Jun; 18(1):72. PubMed ID: 37303048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
